Last updated: September 7, 2026
The gramicidin, neomycin sulfate and polymyxin B sulfate combination is an established ophthalmic antibacterial product sold primarily as a prescription generic. Its commercial profile is defined by low development risk, limited differentiation, mature generic competition and weak pricing power. No meaningful composition-of-matter patent protection or standalone regulatory exclusivity supports the product in the United States. Financial performance depends mainly on manufacturing continuity, wholesaler access, shortage conditions and institutional contracting rather than innovation or brand strength.
What drug is gramicidin, neomycin sulfate and polymyxin B sulfate?
The product is an ophthalmic antibiotic combination containing:
| Active ingredient |
Pharmacologic role |
| Gramicidin |
Gram-positive antibacterial activity |
| Neomycin sulfate |
Aminoglycoside antibacterial activity |
| Polymyxin B sulfate |
Activity against susceptible gram-negative organisms |
The combination is used for susceptible superficial bacterial infections of the eye and surrounding ocular structures. It is generally supplied as an ophthalmic solution. Product labeling states that corticosteroids should not be used when the infection is not adequately controlled because steroids can worsen or mask infection (U.S. Food and Drug Administration [FDA], 2023).
The combination is distinct from common topical skin products containing neomycin, polymyxin B and bacitracin. Gramicidin is the third antibacterial agent in the ophthalmic formulation.
What are the usual strengths and dosage forms?
The ophthalmic solution is commonly labeled with approximately:
- Neomycin sulfate equivalent to 1 mg neomycin base per mL
- Polymyxin B sulfate at 10,000 units per mL
- Gramicidin at 0.025 mg per mL
The commercial product is generally packaged in a sterile multidose dropper bottle. Sterility, container-closure performance and preservative control are important manufacturing requirements.
What is the FDA regulatory status of the combination?
The product is a prescription ophthalmic antibacterial in the United States. It is not a biologic and does not face biosimilar substitution risk. Generic versions can be approved through abbreviated new drug applications if they demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA requirements for ophthalmic products.
The FDA regulatory position has several commercial implications:
- The active ingredients are established drugs.
- The product does not require a new clinical efficacy program for each generic entrant.
- Approval depends heavily on formulation equivalence, sterility, stability and manufacturing controls.
- FDA inspection findings or sterile-manufacturing disruptions can affect supply more rapidly than demand changes.
The product is not comparable to a recently approved specialty medicine with pediatric, orphan or priority-review exclusivity. Its market is driven by generic substitution and procurement economics.
What is the Orange Book status of gramicidin, neomycin sulfate and polymyxin B sulfate?
The combination is treated commercially as a mature generic ophthalmic product. The relevant U.S. exclusivity is not based on an active composition-of-matter patent covering the three-ingredient formulation.
| Exclusivity category |
Commercial assessment |
| New chemical entity exclusivity |
Not applicable |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
No product-specific protection identified |
| New clinical investigation exclusivity |
Not a material market factor |
| Active formulation patent |
No material active protection identified |
| Method-of-use patent |
No material active protection identified |
| Generic ANDA competition |
Central to market structure |
The Orange Book records patents and exclusivity for approved products when applicable. For a mature generic ophthalmic combination, listed patent protection is not the principal barrier to entry. The practical barriers are FDA approval, sterile manufacturing and commercial distribution (FDA, 2024).
What patents protect the ophthalmic combination?
No currently material U.S. patent estate is associated with the active ingredients as a combination. The ingredients have been used in pharmaceutical products for decades, placing any original compound or basic combination claims well beyond ordinary patent terms.
Potentially relevant intellectual-property categories include:
- Container and dropper-device patents
- Preservative systems
- Manufacturing processes
- Sterilization procedures
- Packaging configurations
- Brand trademarks
- Product-specific formulation claims
These rights generally do not create broad exclusion over the active ingredients. A competitor can avoid a narrow device or process claim while marketing an equivalent ophthalmic product.
How strong is the patent estate?
The patent estate is weak from a market-exclusion perspective.
| Patent factor |
Assessment |
| Active-ingredient protection |
Expired or commercially irrelevant |
| Combination protection |
No material active exclusivity identified |
| Formulation protection |
Narrow, if present |
| Device protection |
Potentially relevant but avoidable |
| Manufacturing protection |
May affect process choice, not market entry generally |
| Trademark protection |
Can protect branding, not generic substitution |
| Litigation leverage |
Low |
The absence of a strong patent estate shifts competitive advantage toward manufacturing scale, quality history, supply reliability and channel access.
When does the product lose exclusivity?
The product has already lost the exclusivity associated with its original development. There is no prospective patent-expiration event expected to transform the market. Instead, the commercial market is already in the post-exclusivity phase.
This distinction matters. For a patented branded drug, revenue often falls sharply after a known loss-of-exclusivity date. For this combination, the revenue trajectory is shaped by:
- The number of active generic suppliers
- Contract wins and losses
- Product discontinuations
- FDA manufacturing actions
- Hospital and pharmacy purchasing behavior
- Temporary shortages
- Reimbursement changes
A forecast based on a single patent-expiration date would not describe this product accurately.
How many companies compete in the market?
The market includes branded legacy products, authorized or private-label versions and ANDA-approved generic products. Supplier participation can change as manufacturers discontinue low-margin ophthalmic products or consolidate sterile facilities.
Competition is strongest in the U.S. retail and institutional channels, where buyers can substitute among therapeutically equivalent products when supply is available. The product does not have the commercial concentration associated with a single-source branded medicine.
Which companies are challenging the originator?
The relevant challengers are generic manufacturers filing or marketing ANDA products rather than companies pursuing Paragraph IV patent litigation. Generic ophthalmic suppliers may include large multinational manufacturers, specialty generic companies and private-label distributors.
The commercial challenge is therefore substitution, not patent invalidation. Once multiple equivalent suppliers are available, the originator’s pricing power declines and pharmacy benefit managers, wholesalers and hospitals gain negotiating leverage.
What Paragraph IV challenges affect the product?
Paragraph IV litigation is not a major market event for this mature combination. A Paragraph IV certification is used when an ANDA applicant asserts that a listed patent is invalid, unenforceable or not infringed. That mechanism is most important when an originator has active Orange Book patents.
For gramicidin, neomycin sulfate and polymyxin B sulfate, the absence of material active patent protection means generic entry is more likely to proceed through ordinary ANDA competition than through high-value Paragraph IV disputes. The product does not present the litigation profile of a branded ophthalmic medicine protected by formulation, device or method-of-use patents.
What formulation patents protect the product?
Formulation and manufacturing claims may cover parameters such as:
- Antimicrobial concentration
- pH and osmolality
- Preservative concentration
- Solution stability
- Particulate control
- Sterile filtration
- Container-closure integrity
These claims can create technical work for a generic developer, but they are not equivalent to broad exclusivity over the active ingredients. FDA approval requires the finished product to meet quality specifications, yet a competitor may use a different excipient system or manufacturing process.
For ophthalmic solutions, the most important practical risks are contamination, precipitation, instability and dose-delivery variability. These risks increase development and compliance costs but generally do not support premium pricing.
What market dynamics determine revenue?
Revenue is generated through a low-price, high-substitution model. The product typically competes on availability and contract economics rather than clinical differentiation.
| Revenue driver |
Expected effect |
| Additional generic entrants |
Lower average selling price |
| Supplier exits |
Higher prices during constrained supply |
| Hospital contracts |
Volume growth with margin pressure |
| Retail substitution |
Limits brand retention |
| Manufacturing disruption |
Short-term price and share volatility |
| Stable infection demand |
Supports baseline unit volume |
| Antimicrobial stewardship |
Limits unnecessary use |
The product’s demand is relatively defensive because bacterial eye infections continue to generate treatment needs. Demand growth is limited, however, because the indication is mature and many products compete for the same prescriptions.
No major public pharmaceutical company is likely to report revenue for this combination as a separate line item. Sales are usually aggregated within ophthalmology, generic pharmaceuticals or established brands. As a result, standalone revenue estimates require prescription data, channel sales data or company-specific disclosures rather than public financial statements.
What is the financial trajectory?
The base-case financial trajectory is mature and low growth:
- Unit demand remains broadly stable.
- Average selling prices face long-term erosion from generic substitution.
- Gross margins remain vulnerable to sterile-manufacturing costs.
- Revenue can rise temporarily during supply shortages.
- Long-term value shifts from brand equity to manufacturing reliability.
A manufacturer with efficient sterile production can earn acceptable returns if it maintains high utilization and secures institutional contracts. A manufacturer with small production volumes may face weak economics because ophthalmic quality systems, validation and regulatory compliance create fixed costs.
The product has limited licensing value unless a deal includes:
- A reliable sterile manufacturing platform
- Geographic distribution rights
- A hospital or government supply contract
- A shortage-positioning opportunity
- A broader ophthalmic portfolio
A license covering only the active ingredients would have limited strategic value because the ingredients are not proprietary.
What generic launch risks exist?
Generic launch risk is moderate operationally but low legally.
Regulatory and technical risks
- Failure to demonstrate formulation equivalence
- Sterility failures
- Container-closure defects
- Stability failures
- FDA inspection findings
- Inability to validate aseptic processing
- Product complaints involving particulates or irritation
Commercial risks
- Incumbent suppliers lowering prices
- Wholesaler preference for established vendors
- Low prescription volume
- Contract loss after launch
- Inventory expiry
- Inability to maintain uninterrupted supply
Generic entry can be approved yet commercially unattractive if the supplier cannot achieve scale. This is common in low-price sterile products.
What manufacturing and intellectual-property barriers exist?
The principal barrier is sterile ophthalmic manufacturing, not patent ownership. A qualified supplier needs:
- Validated aseptic processing
- Cleanroom capacity
- Sterile filling equipment
- Microbiological testing
- Stability data
- Reliable active pharmaceutical ingredient supply
- FDA-compliant quality systems
Neomycin sulfate, polymyxin B sulfate and gramicidin must meet identity, potency, purity and microbiological specifications. Supply-chain disruptions involving any one component can interrupt finished-product availability.
Geographic barriers also matter. A company manufacturing outside the United States may need FDA-compliant facilities, import controls, quality agreements and U.S. distribution capability. In Europe and other markets, national authorization and local reimbursement rules create separate entry requirements.
What litigation and settlement agreements affect the product?
No major current patent litigation or high-value generic settlement is central to the commercial profile of this combination. The market is characterized by ordinary generic substitution rather than delayed-entry settlements.
Product-liability, manufacturing and regulatory disputes remain possible. Those matters would normally affect an individual supplier rather than establish industry-wide exclusivity.
How does this combination compare with competing ophthalmic antibiotics?
| Product category |
Patent strength |
Price pressure |
Differentiation |
| Gramicidin/neomycin/polymyxin B |
Low |
High |
Limited |
| Tobramycin ophthalmic |
Low to moderate |
High |
Familiar aminoglycoside profile |
| Ciprofloxacin ophthalmic |
Low |
High |
Fluoroquinolone positioning |
| Moxifloxacin ophthalmic |
Low to moderate |
Moderate to high |
Broader modern prescribing base |
| Branded combination with steroid |
Potentially higher |
Variable |
Combination and brand positioning |
The product can retain a role where prescribers prefer a three-antibiotic formulation, but it lacks the commercial growth profile of newer branded ophthalmic products or combination products with active patent protection.
What is the generic launch scenario?
The most likely scenario is continued multi-source generic supply with periodic price and availability volatility.
| Scenario |
Market outcome |
| Base case |
Stable demand, gradual price erosion, multiple suppliers |
| Supply-constrained case |
Temporary price increases and share gains for available suppliers |
| Consolidation case |
Fewer suppliers, higher disruption risk and improved pricing |
| Demand-decline case |
Reduced use from stewardship or substitution by other antibiotics |
| Branded revival case |
Limited impact unless supported by a differentiated device or contract |
The strongest commercial opportunity is not patent monetization. It is dependable supply in a market where sterile ophthalmic products can experience intermittent shortages.
Key Takeaways
- Gramicidin, neomycin sulfate and polymyxin B sulfate is a mature prescription ophthalmic antibacterial combination.
- The U.S. market is generic and post-exclusivity.
- No material active patent estate or pending patent-expiration event defines the product.
- Paragraph IV litigation and settlement risk are low relative to patented ophthalmic medicines.
- Formulation, sterility, container-closure and manufacturing controls are the main technical barriers.
- Revenue is generally not disclosed separately by public companies.
- Long-term pricing is pressured by generic substitution, while short-term revenue can benefit from supply shortages.
- The most valuable commercial asset is reliable sterile manufacturing and distribution, not the active-ingredient IP.
FAQs
Is gramicidin, neomycin sulfate and polymyxin B sulfate available as a generic?
Yes. The combination is marketed as a prescription generic ophthalmic product in the United States.
Is the product protected by an active U.S. patent?
No material active patent protection covering the core three-ingredient combination is central to its current market.
Can a generic manufacturer launch without a Paragraph IV challenge?
Yes. A generic applicant can pursue approval where no relevant active Orange Book patent blocks entry or where the application does not require a contested patent certification.
Is the combination at risk from biosimilar competition?
No. The product contains small-molecule antibacterial agents and is not a biologic. Biosimilar competition does not apply.
What determines the investment value of this product?
Investment value depends on sterile manufacturing capacity, supply reliability, contract access, regulatory compliance and the number of competing suppliers. Patent duration is not the primary valuation variable.
References
-
U.S. Food and Drug Administration. (2023). Neomycin and polymyxin B sulfates and gramicidin ophthalmic solution prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and generic drug user fee program resources. FDA.
-
U.S. Food and Drug Administration. (2023). Sterile drug products produced by aseptic processing: Current good manufacturing practice guidance for industry. FDA.
